Last updated: February 19, 2026
This analysis examines Australian patent AU2009246926, focusing on its granted claims, the protected subject matter, and the competitive patent landscape. The patent, related to pharmaceutical compositions and methods of treatment, was granted to UCB PHARMA S.A. on February 26, 2015.
What is the Core Innovation Protected by AU2009246926?
The central innovation protected by AU2009246926 pertains to pharmaceutical compositions containing a selective serotonin reuptake inhibitor (SSRI) and a drug that modulates the activity of a voltage-gated sodium channel, specifically a substance that blocks such a channel. The patent claims methods of treating neurological and psychiatric disorders, including epilepsy and chronic pain, using these dual-component compositions.
The described compositions are designed to offer an improved therapeutic effect by combining the action of an SSRI with a sodium channel blocker. This combination aims to address conditions where both serotonergic pathways and neuronal hyperexcitability, often mediated by sodium channels, play a role.
What Specific Subject Matter Does the Patent Cover?
The patent's coverage is defined by its claims, which delineate the legal boundaries of the protected invention. AU2009246926 includes both composition claims and method of treatment claims.
What are the Key Composition Claims?
Claim 1 is representative of the core composition claims. It defines a pharmaceutical composition comprising:
- A selective serotonin reuptake inhibitor (SSRI).
- A substance that blocks the activity of a voltage-gated sodium channel.
The claims further specify that the SSRI and the sodium channel blocker are for use in the treatment of a neurological or psychiatric disorder. The patent provides examples of suitable SSRIs and sodium channel blockers.
Specific details from the claims regarding the components include:
- SSRI Examples: The patent lists several SSRIs, including but not limited to, sertraline, citalopram, escitalopram, fluoxetine, paroxetine, and fluvoxamine.
- Sodium Channel Blocker Examples: The patent refers to substances that block voltage-gated sodium channels. While specific drug names are not exhaustively listed in the primary composition claim, the disclosure broadly encompasses compounds with this mechanism of action. The underlying scientific rationale suggests targeting specific subtypes of sodium channels implicated in neuronal hyperexcitability.
- Dosage and Administration: The claims also implicitly cover various dosage forms and administration routes suitable for pharmaceutical products, although specific dosages are not mandated in the primary claims.
What are the Key Method of Treatment Claims?
The patent claims methods of treating specific disorders using the aforementioned compositions.
- Disorders Targeted: The primary disorders addressed in the claims include, but are not limited to:
- Epilepsy
- Chronic pain (neuropathic pain, inflammatory pain)
- Mood disorders (depression, anxiety disorders)
- Other conditions involving neuronal hyperexcitability.
The method of treatment claims typically involve administering a therapeutically effective amount of the combined SSRI and sodium channel blocker composition to a subject in need thereof.
What is the Scope of Protection Granted?
The scope of protection for AU2009246926 extends to the specific pharmaceutical compositions as defined by the claims and the methods of treating the enumerated disorders using these compositions. The patent grants the patent holder the exclusive right to make, use, sell, and import the patented invention in Australia for the term of the patent.
What are the Limitations and Exclusions?
The scope of protection is inherently limited by the precise wording of the granted claims. Anything falling outside the literal scope of the claims, or specifically excluded by prior art or amendments during prosecution, is not protected.
- Prior Art: The patentability of the claims was assessed against existing knowledge. Any prior art disclosing compositions or methods identical or obvious to the claimed invention would limit the scope.
- Claim Interpretation: The precise interpretation of terms within the claims, such as "selective serotonin reuptake inhibitor" and "substance that blocks the activity of a voltage-gated sodium channel," can be subject to legal interpretation in infringement cases.
- Geographic Limitation: The patent's protection is geographically limited to Australia.
What is the Patent Landscape for Compositions Combining SSRIs and Sodium Channel Blockers?
The patent landscape for combining SSRIs with sodium channel blockers is characterized by a growing interest in multi-target therapies for complex neurological and psychiatric conditions. This area has seen considerable research and patenting activity due to the overlapping roles of serotonin pathways and neuronal excitability in these disorders.
Who are the Key Players in this Patent Space?
Several pharmaceutical companies and research institutions have filed patents related to combinations involving SSRIs and sodium channel blockers or drugs with similar mechanisms. These include:
- UCB Pharma S.A.: The owner of AU2009246926, UCB has a strong focus on neurology and has actively patented its innovations in this therapeutic area.
- Other Major Pharmaceutical Companies: Companies specializing in CNS disorders, pain management, and psychiatry are likely to have a presence in this patent landscape. Examples could include companies with portfolios in epilepsy drugs, antidepressants, and pain therapeutics.
- Academic Institutions and Smaller Biotechs: Research in novel therapeutic combinations often originates in academic settings or smaller biotechnology firms, which may then license or assign their patents to larger entities.
What are the Dominant Trends in Patent Filings?
Trends in patent filings within this space indicate a move towards:
- Novel Combinations: Patents often claim specific combinations of known drugs or novel compounds with specific mechanisms.
- Targeted Indications: Filings are increasingly specifying particular neurological or psychiatric indications, such as treatment-resistant depression, specific types of epilepsy, or subtypes of chronic pain.
- Formulation and Delivery: Innovation is also evident in novel drug formulations that optimize the delivery and synergistic effect of combined agents, improving patient compliance and efficacy.
- Combination Therapies Beyond SSRIs: While AU2009246926 focuses on SSRIs, the broader landscape includes patents on combinations of other antidepressant classes with sodium channel blockers or other neuromodulatory agents.
What is the Competitive Posture of AU2009246926?
AU2009246926 positions UCB Pharma S.A. as a player in the development of dual-action therapies for neurological and psychiatric conditions. The patent provides a period of market exclusivity in Australia for the specific claimed compositions and methods.
How does this Patent Interact with Other Patents?
The interaction of AU2009246926 with other patents depends on the specific claims of those other patents.
- Potential for Overlap: If other patents claim similar compositions (e.g., using different SSRIs or different sodium channel blockers with an overlapping mechanism) or methods for treating the same disorders, there could be potential for patent thickets or design-around strategies by competitors.
- Complementary Patents: Conversely, other patents might cover aspects not claimed by AU2009246926, such as different therapeutic uses, novel formulations, or specific manufacturing processes for the active ingredients.
- Generic Competition: Once the patent expires, generic manufacturers could seek to market their own versions of the combination therapy, provided they do not infringe on any other valid and in-force patents covering the product.
What is the Significance of the Patent Grant Date and Expiry?
The patent was granted on February 26, 2015. As an Australian patent, its standard term is 20 years from the filing date. The filing date for AU2009246926 was October 2, 2009.
- Patent Term: Therefore, the patent is expected to expire around October 2, 2029. This expiry date is critical for market entry strategies for potential competitors.
- Data Protection: In addition to patent term, regulatory data protection provisions in Australia can provide further market exclusivity for approved pharmaceutical products, which may extend beyond the patent expiry date.
What are the Implications for R&D and Investment Decisions?
The analysis of AU2009246926 offers several critical insights for R&D and investment decisions:
- Therapeutic Area Focus: The patent highlights UCB's strategic interest in developing combination therapies for neurological and psychiatric disorders, particularly epilepsy and chronic pain. Companies operating in these therapeutic areas need to be aware of UCB's patented territory.
- Mechanism of Action: The focus on combining SSRIs with sodium channel blockers suggests a scientific rationale for targeting both mood regulation and neuronal excitability. R&D efforts could explore similar synergistic mechanisms or alternative targets within these pathways.
- Competitive Intelligence: For companies developing or considering developing therapies for epilepsy, chronic pain, or mood disorders, understanding the claims of AU2009246926 is essential to avoid infringement. This necessitates thorough freedom-to-operate (FTO) analyses.
- Investment Opportunities: Investors can assess opportunities in companies developing novel treatments for these indications. The patent landscape can inform due diligence by highlighting areas with existing IP protection and potential white spaces for innovation. Investing in companies with a strong IP portfolio in these areas can mitigate risk.
- Partnership and Licensing: Companies looking to enter these markets or expand their offerings might consider licensing opportunities related to UCB's patent or seeking alternative IP strategies.
- Future Innovation: The expiry date of October 2, 2029, indicates a window for potential market entry by competitors. However, innovation in drug formulation, novel combinations, or improved treatment regimens could lead to new patent filings that extend market exclusivity.
Table 1: Key Details of Australian Patent AU2009246926
| Feature |
Detail |
| Patent Number |
AU2009246926 |
| Applicant/Owner |
UCB PHARMA S.A. |
| Grant Date |
February 26, 2015 |
| Filing Date |
October 2, 2009 |
| Patent Term Expiry |
Approximately October 2, 2029 |
| Core Invention |
Pharmaceutical compositions comprising SSRIs and sodium channel blockers. |
| Primary Applications |
Treatment of epilepsy, chronic pain, mood disorders, and other neurological conditions. |
| Jurisdiction |
Australia |
Key Takeaways
- Australian patent AU2009246926 protects pharmaceutical compositions containing a selective serotonin reuptake inhibitor (SSRI) and a sodium channel blocker for treating neurological and psychiatric disorders, primarily epilepsy and chronic pain.
- The patent was granted to UCB Pharma S.A. on February 26, 2015, and is expected to expire around October 2, 2029.
- The patent landscape for such combinations is active, with UCB Pharma S.A. holding a position of exclusivity in Australia for its claimed invention.
- Companies considering R&D or investment in this space must conduct thorough freedom-to-operate analyses to navigate existing intellectual property rights.
FAQs
-
What specific sodium channel blockers are covered by the patent?
The patent broadly claims "a substance that blocks the activity of a voltage-gated sodium channel." While specific examples are not exhaustively listed in the primary composition claim, the disclosure implies compounds with established efficacy in blocking these channels, particularly those implicated in neuronal hyperexcitability. The exact scope would be subject to detailed claim construction.
-
Does this patent prevent the use of SSRIs or sodium channel blockers individually for treating these conditions?
No, AU2009246926 specifically protects the combination of an SSRI and a sodium channel blocker. It does not prevent the marketing or use of SSRIs or sodium channel blockers as monotherapies for their respective approved indications, as long as those monotherapies are not infringing on other patents.
-
Can a generic company market a combination product once this patent expires in Australia?
A generic company could potentially market a combination product after the expiry of AU2009246926, provided they do not infringe on any other valid and in-force patents covering the specific combination, active pharmaceutical ingredients, or manufacturing processes. Regulatory approval and data protection periods must also be considered.
-
Are there any approved drugs on the Australian market that are directly covered by this patent?
Determining if an approved drug is directly covered by AU2009246926 requires a direct comparison of the drug's composition and proposed use against the exact wording of the granted claims. This analysis is beyond the scope of this general landscape review and would necessitate a detailed freedom-to-operate opinion.
-
What is the likely strategy of UCB Pharma S.A. regarding this patent?
UCB Pharma S.A. likely aims to leverage this patent for market exclusivity in Australia for their specific combination therapy. This exclusivity is intended to recoup R&D investment and generate revenue. Their strategy may also involve developing specific formulations or therapeutic regimens that further differentiate their product and potentially attract additional patent protection.
Citations
[1] UCB PHARMA S.A. (2015, February 26). Australian Patent AU2009246926: Pharmaceutical compositions and their use in the treatment of neurological and psychiatric disorders. IP Australia.
